Micheli Laura, Di Cesare Mannelli Lorenzo, Mosti Elena, Ghelardini Carla, Bilia Anna Rita, Bergonzi Maria Camilla
Department of Neuroscience, Psychology, Drug Research and Child Health-NEUROFARBA-Pharmacology and Toxicology Section, University of Florence, Viale G. Pieraccini 6, 50139 Florence, Italy.
Department of Chemistry Ugo Schiff, University of Florence, Via Ugo Schiff 6, Sesto Fiorentino, 50019 Florence, Italy.
Pharmaceutics. 2023 May 17;15(5):1516. doi: 10.3390/pharmaceutics15051516.
Tendinopathies represent about 45% of musculoskeletal lesions and they are a big burden in clinics characterized by activity-related pain, focal tendon tenderness and intra-tendinous imaging changes. Many approaches have been proposed for tendinopathies' management (e.g., nonsteroidal anti-inflammatory drugs, corticosteroids, eccentric exercises, laser therapy), unfortunately with very little support of efficacy or serious side effects, thus making the identification of new treatments fundamental. The aim of the study was to test the protective and pain reliever effect of thymoquinone (TQ)-loaded formulations in a rat model of tendinopathy induced by carrageenan intra-tendon injection (20 µL of carrageenan 0.8% on day 1). Conventional (LP-TQ) and hyaluronic acid (HA)-coated TQ liposomes (HA-LP-TQ) were characterized and subjected to in vitro release and stability studies at 4 °C. Then, TQ and liposomes were peri-tendon injected (20 µL) on days 1, 3, 5, 7 and 10 to evaluate their antinociceptive profile using mechanical noxious and non-noxious stimuli (paw pressure and von Frey tests), spontaneous pain (incapacitance test) and motor alterations (Rota rod test). Liposomes containing 2 mg/mL of TQ and covered with HA (HA-LP-TQ2) reduced the development of spontaneous nociception and hypersensitivity for a long-lasting effect more than the other formulations. The anti-hypersensitivity effect matched with the histopathological evaluation. In conclusion, the use of TQ encapsulated in HA-LP liposomes is suggested as a new treatment for tendinopathies.
肌腱病约占肌肉骨骼损伤的45%,是临床中的一个重大负担,其特征为与活动相关的疼痛、局部肌腱压痛和肌腱内影像学改变。针对肌腱病的治疗已提出了许多方法(如非甾体抗炎药、皮质类固醇、离心运动、激光治疗),但遗憾的是,这些方法在疗效方面缺乏有力支持或存在严重副作用,因此确定新的治疗方法至关重要。本研究的目的是在通过卡拉胶肌腱内注射(第1天注射20 μL 0.8%的卡拉胶)诱导的肌腱病大鼠模型中,测试载有百里醌(TQ)的制剂的保护和止痛效果。对常规(LP-TQ)和透明质酸(HA)包被的TQ脂质体(HA-LP-TQ)进行了表征,并在4℃下进行了体外释放和稳定性研究。然后,在第1、3、5、7和10天进行肌腱周围注射(20 μL)TQ和脂质体,使用机械性有害和无害刺激(爪部压力和von Frey试验)、自发疼痛(失能试验)和运动改变(转棒试验)来评估它们的抗伤害感受情况。含有2 mg/mL TQ并被HA覆盖的脂质体(HA-LP-TQ2)比其他制剂更能长期减少自发伤害感受和超敏反应的发展。抗超敏反应效果与组织病理学评估结果相符。总之,建议将HA-LP脂质体包裹的TQ用作肌腱病的一种新治疗方法。